Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528240 | 0.83 | ALDH1A1 (0.46) | ALDH1A1GAALMNAMAPTKMT2A | |
| SCHEMBL3526988 | 0.80 | HDAC3 (0.42) | ALDH1A1LMNASMN1; SMN2MAPTPKM | |
| SCHEMBL3526734 | 0.80 | CCR9 (0.49) | ALDH1A1 | |
| SCHEMBL3520054 | 0.78 | LMNA (0.57) | ALDH1A1GAALMNASMN1; SMN2MAPT | |
| SCHEMBL3524774 | 0.76 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL3529176 | 0.76 | MAPT (0.43) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL3525917 | 0.76 | HDAC3 (0.41) | ALDH1A1LMNASMN1; SMN2MAPTPKM | |
| SCHEMBL3525396 | 0.75 | ALDH1A1 (0.44) | ALDH1A1GAAKMT2APKM | |
| SCHEMBL3520224 | 0.75 | TRPV1 (0.45) | ALDH1A1LMNASMN1; SMN2MAPTPKM | |
| SCHEMBL3522354 | 0.75 | LMNA (0.46) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | EPHX2 1151/4885ALDH1A1 1607/4885GAA 772/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | EPHX2 2086/4885ALDH1A1 1453/4885GAA 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.